The frequency of germline mutations in melanoma susceptibility genes (CDKN2A (cyclin-dependent kinase inhibitor 2A), CDK4 (cyclin-dependent kinase 4), MITF (microphtalmia-associated transcription factor), POT1 (protection of telomeres 1)/ACD/TERF2IP, TERT, and BAP1) is lower than expected in MPM patients7,9–11. Here, CDKN2A is linked to melanoma.